Srinagar Magazine

The Pancreatic Ductal Adenocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pancreatic Ductal Adenocarcinoma Market.

Some of the key takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Pancreatic Ductal Adenocarcinoma treatment therapies with a considerable amount of success over the years. 
• Pancreatic Ductal Adenocarcinoma companies working in the treatment market are Elicio Therapeutics, General Oncology, Inc., Revolution Medicines, Amplia Therapeutics, ZielBio, Lisata Therapeutics, Inc., Cardiff Oncology, Eucure Biopharma, Panbela Therapeutics, Inc., Jiangsu Alphamab Biopharmaceuticals, Novartis Pharmaceuticals, Cantargia, Eucure Biopharma, Arcus Biosciences, Syntrix Biosystems, and others, are developing therapies for the Pancreatic Ductal Adenocarcinoma treatment 

• Emerging Pancreatic Ductal Adenocarcinoma therapies such as – ELI-002, Melphalan, RMC-6236, AMP 945, ZB131, CEND-1, Onvansertib, YH003, SBP-101, KN046, NIS793, Nadunolimab, YH 003, Zimberelimab, SX 682, and others are expected to have a significant impact on the Pancreatic Ductal Adenocarcinoma market in the coming years.   
• In January 2022, In order to compare the effectiveness and safety of KN046 combined with Gemcitabine and Nab-Paclitaxel versus placebo combined with Gemcitabine and Nab-Paclitaxel in first-line Advanced Pancreatic Ductal Adenocarcinoma subjects (ENREACH-PDAC-01), Jiangsu Alphamab Biopharmaceuticals started a multicenter, randomized, double-blind Phase III study
• In July 2022, Cend Therapeutics, Inc. reported that data from the Phase 1b study of CEND-1, Cend’s lead investigational drug, in combination with gemcitabine and nab-paclitaxel for the treatment of first-line, metastatic pancreatic ductal adenocarcinoma (“mPDAC”) were published in The Lancet Gastroenterology and Hepatology
• In July 2022, I-Mab reported that a Phase 1 international multi-center clinical trial (IMCT) for patients with solid tumours, such as gastric cancer, gastroesophageal junction carcinoma, esophageal adenocarcinoma, and pancreatic ductal carcinoma, has treated the first patient in China with TJ-CD4B (also known as ABL111), a novel Claudin 18.2 x 4-1BB bispecific antibody
• In June 2022, The mRNA-based personalized neoantigen-specific immunotherapy (iNeST) autogene cevumeran (also known as BNT122, RO7198457) in combination with the anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC) was recently evaluated for safety and tolerability in a first-in-human Phase 1 study. It was confirmed that the method of tumour profiling for individualized vaccine design and on-demand production of iNeST in a therapeutically appropriate period is feasible. The early findings revealed a good safety profile and encouraging hints of clinical activity
• In June 2022, In order to move Motixafortide through a randomized Phase 2b clinical trial in pancreatic ductal adenocarcinoma, or PDAC, BioLineRx Ltd. stated that the firm had entered into a collaboration agreement with GenFleet Therapeutics, an immuno-oncology-focused biopharmaceutical firm with headquarters in China
• In November 2021, Alphamab Oncology announced that the IND application for phase III registration study(KN046-303) of the PD-L1/CTLA-4 bispecific antibody KN046 plus nab-paclitaxel/gemcitabine for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) was approved by the Center for Drug Evaluation (CDE) of the NMPA

Pancreatic Ductal Adenocarcinoma Overview

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive lethal malignancy due to the lack of early diagnosis and limited response to treatments. It is the most prevalent type of pancreatic neoplasm, and it is developed in the exocrine compartment and accounts for more than 90% of pancreatic cancer cases.

Get a Free Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight

Emerging Pancreatic Ductal Adenocarcinoma Drugs Under Different Phases of Clinical Development Include:

• ELI-002: Elicio Therapeutics
• Melphalan: General Oncology, Inc.
• RMC-6236: Revolution Medicines
• AMP 945: Amplia Therapeutics
• ZB131: ZielBio
• Nadunolimab: Cantargia
• Zimberelimab: Arcus Biosciences
• CEND-1: Lisata Therapeutics, Inc
• Onvansertib: Cardiff Oncology
• YH003: Eucure Biopharma
• SBP-101: Panbela Therapeutics, Inc.
• KN046: Jiangsu Alphamab Biopharmaceuticals
• NIS793: Novartis Pharmaceuticals

Route of Administration

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics Assessment

• Pancreatic Ductal Adenocarcinoma Assessment by Product Type
• Pancreatic Ductal Adenocarcinoma By Stage and Product Type
• Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration
• Pancreatic Ductal Adenocarcinoma By Stage and Route of Administration
• Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type
• Pancreatic Ductal Adenocarcinoma by Stage and Molecule Type
•  

DelveInsight’s Pancreatic Ductal Adenocarcinoma Report covers around 80+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Pancreatic Ductal Adenocarcinoma product details are provided in the report. Download the Pancreatic Ductal Adenocarcinoma pipeline report to learn more about the emerging Pancreatic Ductal Adenocarcinoma therapies

Some of the key companies in the Pancreatic Ductal Adenocarcinoma Therapeutics Market include:

Key companies developing therapies for Pancreatic Ductal Adenocarcinoma are – Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others.

Pancreatic Ductal Adenocarcinoma Pipeline Analysis:

The Pancreatic Ductal Adenocarcinoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Ductal Adenocarcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Ductal Adenocarcinoma Treatment.
• Pancreatic Ductal Adenocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pancreatic Ductal Adenocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Ductal Adenocarcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma drugs and therapies

Pancreatic Ductal Adenocarcinoma Pipeline Market Drivers

• Increasing pervasiveness of the disease, increasing demand of targeted therapy are some of the important factors that are fueling the Pancreatic Ductal Adenocarcinoma Market.

Pancreatic Ductal Adenocarcinoma Pipeline Market Barriers

• However, Lack of early diagnostic markers, complicated and multifactorial nature of disease, diverse genetics and rapid metastasis and other factors are creating obstacles in the Pancreatic Ductal Adenocarcinoma Market growth.

Scope of Pancreatic Ductal Adenocarcinoma Pipeline Drug Insight    

• Coverage: Global
• Key Pancreatic Ductal Adenocarcinoma Companies: Elicio Therapeutics, General Oncology, Inc., Revolution Medicines, Amplia Therapeutics, ZielBio, Lisata Therapeutics, Inc., Cardiff Oncology, Eucure Biopharma, Panbela Therapeutics, Inc., Jiangsu Alphamab Biopharmaceuticals, Novartis Pharmaceuticals, Cantargia, Eucure Biopharma, Arcus Biosciences, Syntrix Biosystems, and others
• Key Pancreatic Ductal Adenocarcinoma Therapies: ELI-002, Melphalan, RMC-6236, AMP 945, ZB131, CEND-1, Onvansertib, YH003, SBP-101, KN046, NIS793, Nadunolimab, YH 003, Zimberelimab, SX 682, and others
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment: Pancreatic Ductal Adenocarcinoma current marketed and Pancreatic Ductal Adenocarcinoma emerging therapies
• Pancreatic Ductal Adenocarcinoma Market Dynamics: Pancreatic Ductal Adenocarcinoma market drivers and Pancreatic Ductal Adenocarcinoma market barriers 

Request for Sample PDF Report for Pancreatic Ductal Adenocarcinoma Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services